Drug Deal Disclosure Act

Sponsor: Judy Chu (Democratic-CA)July 15, 2026

AI-generated ?

Report an error

Introduced

In Committee

Passed One Chamber

Passed Both Chambers

Signed into Law

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Requires federal agencies to reveal private drug pricing deals with drug makers.

This bill would make federal agencies publicly share details about private drug pricing agreements they've made with drug companies. This means people would get to see how certain drug prices are set. They would also see what other deals are included, such as those affecting Medicare and Medicaid. The goal is to bring more transparency to how drug prices are negotiated.

What Would Change

Today, the details of private drug pricing agreements between federal agencies and drug manufacturers are generally kept confidential. If this bill passes, the Department of Health and Human Services would be required to publicly release these records. This includes specific agreements made since January 20, 2025, and all future deals. This change would provide the public with a centralized, searchable database of these agreements and an analysis of their economic impact.

Key Provisions

Requires the Department of Health and Human Services (HHS) to publicly release records about federal drug pricing deals.
Mandates HHS to disclose specific past agreements with 17 major drug manufacturers, including Pfizer and Johnson & Johnson.
Requires HHS to disclose new or changed drug pricing deals with drug manufacturers within 30 days of them being made.
Blocks federal agencies from hiding information due to reputational harm or political sensitivity.
Allows HHS to redact some proprietary pricing details, but only with a public explanation and submission to Congress.
Requires the Congressional Budget Office and Government Accountability Office to study the economic effects of these disclosed deals.

View on Congress.gov

HR 9699 · 119th Congress · July 15, 2026 · AI Summary by gemini-2.5-flash · 10/10

Drug Deal Disclosure Act

What Would Change

Key Provisions

Lobbying Activity